Pre-market US Stock News Roundup: SpaceX Eyes Rights to 80,000 US Cell Towers, Jensen Huang Says Memory Oversupply Unlikely

2026-10-23 20:32 (UTC+8)

Odaily: Ahead of the US market open, the key market and financial news investors should watch is as follows:

1. The three major US stock index futures fell collectively. Dow Jones futures dropped 0.78%, S&P 500 futures fell 0.35%, and Nasdaq 100 futures declined 0.17%.

2. International oil prices rose across the board. WTI crude oil futures climbed 1.87% to $101.326 per barrel; Brent crude oil futures rose 1.59% to $114.964 per barrel.

3. International spot gold and silver moved in mixed directions. Spot gold rose 0.12% to $4,029.05 per ounce; spot silver fell 1.36% to $53.82 per ounce.

4. Europe's three major stock indices fell across the board. The UK's FTSE 100 dropped 0.55%, France's CAC40 fell 0.76%, and Germany's DAX30 declined 0.94%.

5. Intel's chief technology officer said that even with ample funding, global cutting-edge wafer output would be hard-pressed to expand tenfold, with a more realistic growth ceiling of about twofold. The key equipment, cleanrooms, and fab scale needed to manufacture advanced chips are becoming the new capacity ceiling.

6. Nvidia CEO Jensen Huang said on Thursday that the memory chip industry is unlikely to face oversupply by 2029. He noted, "One of the great things about memory is that you can always use more. HBM will continue to see widespread adoption for years to come."

7. The US Federal Communications Commission (FCC) approved a one-year waiver for Intel on the 22nd local time, exempting it from import restrictions targeting certain foreign-made advanced robotics equipment.

8. SpaceX plans to obtain rights to at least 80,000 cell towers within the United States and is in talks with at least one major cellular infrastructure company. If an agreement is reached, SpaceX could become the fourth nationwide wireless carrier in the US.

9. Partial clinical trial data for the personalized cancer vaccine Intismeran autogene, jointly developed by Moderna and Merck, leaked ahead of schedule. Analysts view the overall trial results as positive.

10. OpenAI's financing negotiations are nearing completion, seeking to raise about $30 billion, with its valuation target reportedly lowered to $1.25 trillion.

11. Bank of America expects risk-off sentiment to persist until mid-November, with US Treasury yields, US stocks, and the dollar potentially falling in tandem.